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Polycationing cationic polyelectrolyte, restores the adsorption of the clinical lung surfactant
Survanta to the air–water interface in the presence of albumin at much lower concentrations than uncharged
polymers such as polyethylene glycol. This is consistent with the positively charged chitosan forming ion
pairs with negative charges on the albumin and lung surfactant particles, reducing the net charge in the
double-layer, and decreasing the electrostatic energy barrier to adsorption to the air–water interface.
However, chitosan, like other polyelectrolytes, cannot perfectly match the charge distribution on the
surfactant, which leads to patches of positive and negative charge at net neutrality. Increasing the chitosan
concentration further leads to a reduction in the rate of surfactant adsorption consistent with an over-
compensation of the negative charge on the surfactant and albumin surfaces, which creates a new repulsive
electrostatic potential between the now cationic surfaces. This charge neutralization followed by charge
inversion explains the window of polyelectrolyte concentration that enhances surfactant adsorption; the
same physical mechanism is observed in ﬂocculation and re-stabilization of anionic colloids by chitosan and
in alternate layer deposition of anionic and cationic polyelectrolytes on charged colloids.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionMonolayer ﬁlms of lung surfactant (LS) line the alveolar air–water
interface and lower the interfacial tension in the lungs, thereby
minimizing the work of breathing [1,2]. The surface tension control
imposed by LS can be compromised during acute respiratory distress
syndrome (ARDS), which afﬂicts 140,000 people annually in the US
with a 40%mortality rate [3–5]. The clinical similarities between ARDS
and neonatal RDS have led to the hypothesis that the same lack of
functional surfactant that causes NRDS might be a common factor.
Surfactant replacement therapy is the primary treatment for pediatric
patients with NRDS [6–8], but there has been less success with ARDS
and other forms of lung injury [9]. A contributing factor to the
development and severity of ARDS may be the elevated serum and
inﬂammatory protein levels in the bronchial and alveolar ﬂuid of
ARDS patients [2,10–13]. In vitro, there is an ARDS-like depression of
LS activity when serum proteins are added to a LS-covered interface
[14,15], LS is added to a serum-covered interface [16,17] or both LS and
serum proteins are presented simultaneously [18].
A necessary [16,17,19–21], but not sufﬁcient condition [5,22], for
surfactant activity is to have sufﬁcient LS transported to the interface
from the type II cells that line the alveoli. Previous work has shown
that the competitive adsorption of serum proteins to the air–water
interface can inhibit the adsorption of lung surfactant, leading to poor1 805 893 4731.
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ll rights reserved.surfactant performance [14–18,20,21,23,24]. Many serum proteins are
surface-active and have a surface pressure,Π, (Π=γw−γ ; γw is the
surface tension of a clean air–water interface, 72 mN/m, and γ the
measured surface tension) that is a logarithmic function of protein
concentration up to a saturation concentration, which is ∼1 mg/mL
for albumin [15,25]. The surface pressure at the saturation concentra-
tion for albumin and many other serum proteins is between 18 and
25 mN/m (γ ∼47–54 mN/m) [15,25], which is much lower than
Π∼70 (γ near zero) required for proper respiration.
Albumin (as well as any other surface-active material) adsorbed at
the alveolar air–water interface induces an energy barrier that inhibits
surfactant transport to the interface, thereby slowing surfactant
adsorption [16–18,21,26,27]. The physical processes governing surfac-
tant transport to an interface are identical to those that determine
colloid stability; the energy barrier that limits surfactant adsorption in
the presence of serum proteins is directly analogous to those that lead
to colloid stability against aggregation [17,20,21]. Hence, it should not
be surprising that many of the same additives used to lower the
energy barrier and promote colloid aggregation [28–35] lead to
enhanced surfactant adsorption. The ﬁrst examples of the analogy
between colloid stability and surfactant adsorption came from
observations that adding non-ionic hydrophilic polymers such as
polyethylene glycol (PEG) and dextran [18,23,36–38] or anionic
polymers such as hyaluronic acid [39,40] to clinical surfactants
improved lung function of animals over that of surfactant alone.
This improved lung function correlated well with enhanced surfactant
adsorption to an albumin-covered air–water interface in vitro, as well
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[17,19–21,27]. Both the enhanced adsorption to the air–water interface
[41] and ﬂocculation of the surfactant aggregates in suspension [42]
could be explained as originating from the depletion attraction that
entropically pushes the surfactant aggregates toward the interface
and toward each other, thereby overcoming an albumin-induced
energy barrier [21].
This albumin-induced energy barrier to surfactant adsorption is
primarily electrostatic [19,26]; a double-layer repulsion arises due to
the negative lipids in lung surfactant and the net negative charge on
albumin (and other surface-active serum proteins) at the interface
[28]. Classical methods of manipulating the double-layer repulsion in
colloids using electrolytes have similar, predictable effects on
surfactant adsorption. Decreasing the electrolyte concentration
below physiological levels increases the Debye length and the
magnitude and range of the double layer repulsion, which eliminates
surfactant adsorption even in the presence of the polymer-induced
depletion attraction [19]. Conversely, increasing the bulk electrolyte
concentration well above physiological levels restores surfactant
adsorption in the presence of albumin without the need for added
polymer [19,26].
The third common method of stabilizing or ﬂocculating charged
colloids, which has a long history in wastewater treatment, mineral
processing, ceramics manufacture and papermaking, relies on adding
oppositely charged polyelectrolytes [30–35]. Cationic polyelectrolytes,
such as chitosan, are particularly useful, as they are oppositely
charged to the negatively charged surfaces common to biological
systems. In analogy to its effects on colloid stability, chitosan
improves the performance of lung surfactant in vitro [24,43]. Here
we show that only 0.001 mg/mL chitosan is able to reverse albumin-
induced surfactant inhibition to the same extent as ∼10 mg/mL
10 kDa PEG [16,17,20,21,27] or ∼1 mg/mL 1240 kDa hyaluronic acid
[16,21] under otherwise identical conditions. These chitosan concen-
trations are much too low to induce a depletion attraction, which is
proportional to the polymer volume fraction [21,41,42,44]. However,
unlike PEG or HA, increasing the chitosan concentration above
optimal causes surfactant inhibition to re-occur. The chitosan
concentration range that reverses inhibition is roughly that necessary
to neutralize the negative charge on a given concentration of
Survanta. This charge neutralization mechanism is identical to that
observed in ﬂocculation of colloidal particles by chitosan and other
cationic polyelectrolytes [30–35]. At the chitosan concentration is
increased, the net negative charge in the double-layer surrounding
both Survanta and albumin are neutralized, leading to an elimination
of the electrostatic repulsion between the Survanta and the albumin-
covered interface [30–35]. However, as is often the case for
polyelectrolytes, increasing the polymer concentration further leads
to additional chitosan binding to the surfaces resulting in an over-
compensation of the surface charge. This re-establishes an electro-
static energy barrier [30–35] and leads to a decrease in surfactant
adsorption. The same physical mechanism is observed in ﬂocculation
and re-stabilization of anionic colloids by chitosan [30–32] and in
alternate layer deposition of anionic and cationic polyelectrolytes on
charged colloids [33]. These results conﬁrm the fundamental
importance of electrostatics in determining the competitive adsorp-
tion of surfactant as well as the analogy between surfactant
adsorption and colloid stability.
2. Methods
Survanta (Abbott Laboratories, Columbus, Ohio) was a generous
gift of the Santa Barbara Cottage Hospital nursery. Survanta is an
organic extract of minced bovine lungs that has been fortiﬁed with
dipalmitoylphosphatidylcholine (DPPC), tripalmitin and palmitic acid.
Survanta contains 80–90% wt. phosphatidylcholine, of which, ∼70%
wt. is saturated DPPC and about 10% wt. palmitic acid [45,46]. Thepreparation contains approximately 7% wt. negatively charged
phospholipids including phosphatidylglycerol and phosphatidylserine
giving the Survanta aggregates a net negative charge [46]. Survanta
has minimal amounts of SP-B, 0.04–0.13% wt. but close to native
amounts of SP-C, 0.9–1.65% wt. [45,47,48]. Both SP-B and SP-C are
cationic, which partially compensates the negative charge on the
lipids. Like other natural products, Survanta can vary somewhat from
batch to batch due to variations in extraction and puriﬁcation as well
as variations in the source materials. Survanta and other clinical lung
surfactants form multi-micron bilayer aggregates in buffered saline
solution [47]. Bovine serum albumin, 75–85% deacetylated chitosan
(∼50–190 kDa) and palmitic acid (PA) were obtained from Sigma (St.
Louis, MO) and used as received.
Isotherms were recorded at 25 °C (no signiﬁcant changes are seen
from 23–37 °C [49]) using a custom stainless steel ribbon trough
(Nima, Coventry, England) designed to minimize ﬁlm leakage at high
surface pressures (low surface tensions). Surface pressure was
monitored during compression and expansion using a ﬁlter paper
Wilhelmy plate. The trough had a surface area of 130 cm2; a subphase
volume of 150 mL and a typical compression/expansion cycle took
8 min (∼0.42 cm2/s). All water used in experiments was obtained
from a Millipore Gradient System (Billerica, MA) and had a resistivity
of 18.2 MΩ/cm. The buffered-saline subphase contained 150 mM
NaCl, 2 mM CaCl2, 0.2 mM NaHCO3 in addition to the stated
concentrations of albumin and chitosan. For experiments with
chitosan, the solution pH was reduced to ∼2.0 with 1 M HCl until a
clear solution was obtained after adding chitosan; the pH of the
solutionwas then raised to ∼5.5 with 1 M NaOH. The subphase pH for
all experiments was held at ∼5.5; as the pKa for chitosan is ∼6.5, ∼90%
of the amine groups are positively charged. For an average chitosan
molecular weight of 120 kDawith ∼80% of the repeat units containing
an amine group, this yields ∼500 positive charges per molecule.
To initiate each experiment, a saline-buffered subphase containing
albumin and chitosan was added to the Langmuir trough and allowed
to equilibrate for 10 min. For albumin containing subphases, the
surface pressure gradually increased to ∼18 mN/m consistent with
the well-established relation between surface activity and albumin
concentration [15,25]. Chitosan in buffer showed no surface activity
(Fig. 3). For all experiments, Survanta was diluted in a standard buffer
(150 mM NaCl, 2 mM CaCl2, 0.2 mM NaHCO3, pH=7.0) to a lipid
concentration of 2 mg/mL and was deposited as microliter drops from
a syringe by touching the drop to the air–water interface of the open
trough. The drops passed through the interface into the subphase
adjacent to the interface; surfactant adsorption from the subphase
was followed by labelling the Survanta with 1 mol% of the ﬂuorescent
lipid Texas Red-DHPE (Invitrogen, Eugene, OR). The drops did not
spread appreciably at the interface and essentially all of the Survanta
adsorbed from the subphase [17]. The subphase was not stirred and
the ﬁrst compression began 20min after deposition of a ﬁxed quantity
of Survanta. The amount of Survanta chosen for the inhibition
experiments, 800 μg, was such that collapse would occur at about
50% trough compression in the absence of albumin; the same amount
of surfactant was used in all subsequent experiments.
A Nikon Optiphot optical microscope (Nikon, Tokyo, Japan) with
either a 10× or 50× extra longworking distance objective designed for
ﬂuorescent light [50] was positioned above the trough. Full-length
movies and individual frames were recorded directly to computer
(Moviestar, Mountain View, CA). Contrast in the images was due to
segregation of 1% mol ﬂuorescent lipid Texas Red-DHPE (Invitrogen,
Eugene, OR) between the liquid expanded and condensed phases
which causes the Survanta monolayer to have a light gray–dark gray
coexistence in images [17,49]. Larger aggregates of Survanta have
signiﬁcantly more dye than the monolayer ﬁlm and appear bright
white, leading to an overall mottled texture for the surfactant ﬁlm. The
albumin was not labeled, does not ﬂuoresce and appears black in the
images.
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Fig. 1a shows a typical compression–expansion cyclic isotherm for
800 μg of Survanta adsorbing to a buffered-saline interface. The
isotherm traces over itself on subsequent cycles and on compression
exhibits a characteristic shoulder at Π∼45 mN/m and collapse
plateau at πmax∼69 mN/m where the ﬁlm begins to “collapse” and
form cracks and folds [17,49,51,52]. Film collapse determines the
minimum surface tension possible for a given surfactant. The
hysteresis between compression and expansion cycles is typical of
Survanta and other clinical and natural lung surfactant isotherms
[2,53] Expanding the interface after monolayer collapse leads to a
rapid drop in surface pressure to a minimum of 5–10 mN/mwhich is
maintained until compression is resumed. There is no signiﬁcant
change in the Survanta isotherms from 23–37 °C [49].
Conversely, when the same amount of Survanta (800 μg) is
deposited onto a subphase containing 2 mg/mL albumin (Fig. 1b,
black curve), the surface pressure does not increase above 42 mN/m
even at the smallest trough area. The concentration of albumin used
here are above the ∼1 mg/ml saturation concentration at which the
albumin surface pressure no longer increases with concentration
[15,25]. Reports of the average albumin concentrations in the alveolar
ﬂuid of ARDS patients and healthy patients vary widely. Estimates
range from 0.5 mg/mL for ARDS patients compared to 0.03 mg/mL for
healthy patients [13] to 25 mg/mL for ARDS patients compared to
5 mg/mL for healthy patients [12].Fig. 1. (a) Cyclic isotherms of 800 μg Survanta deposited from an aqueous buffer onto a salin
exhibits a characteristic shoulder at 45 mN/m and a collapse plateau atΠmax∼69 mN/m. On
∼5–10 mN/m until compression is resumed. (b) Black curve: 800 μg Survanta added to a s
collapse plateau on compression seen in (a) cannot be reachedwith albumin in the subphase
mL albumin,with no added Survanta or chitosan. The two curves trace over each other, indicat
the interface. (c) 800 μg Survanta deposited on a subphase containing 2mg/mL albumin and
collapse plateau have been restored at similar trough areas as in (a) showing that the presenc
only difference with the Survanta isotherms in panel a is that the minimum surface pressure
corresponds to the equilibrium spreading pressure of the albumin. (d) 800 μg Survanta depos
areas, the isotherm resembles that of albumin (panel b), while at low trough areas, the chara
pressure of∼60 and the collapse plateau does not form at the limiting compression. This indica
to panel c.The characteristic shoulder and collapse plateau seen upon
compression in Fig. 1a cannot be reached with albumin in the
subphase at this Survanta concentration; a ﬁve fold increase in
Survanta concentration yields only a partial recovery of these features
[17]. Theminimum surface pressure (∼15mN/m) during expansion in
Fig. 1b is higher than Fig. 1a and is set by the re-adsorption of albumin
to the interface at its saturation surface pressure [15]. Both the
compression and expansion isotherms are not different than that of
albumin alone (Fig. 1b, red curve), indicating that albumin has
excluded the Survanta from the interface (see Fig. 4b). Albumin at
these compression rates can signiﬁcantly exceed its equilibrium
surface pressure of ∼18 mN/m.
Fig. 1c shows Survanta (800 μg) deposited onto a subphase
containing 2 mg/mL albumin and 0.005 mg/mL chitosan; the
isotherm resembles Survanta on a clean interface (Fig. 1a) by the
second compression-expansion cycle. Subphase chitosan does not
alter the surface pressure at which the characteristic shoulder
(Π∼45 mN/m) and collapse plateau (Πmax∼69 mN/m) occur but
rather enhances the adsorption of surfactant to the interface and the
displacement of albumin from the interface. The major change
between Fig. 1a and c is that the minimum surface pressure during
expansion never drops below ∼15 mN/m (which is the equilibrium
surface pressure of the albumin)when albumin is present (see Fig.1b)
[15]. The restoration of the Survanta isotherm (Fig. 1a) during
subsequent compression cycles in Fig. 1c shows that the rate of
surfactant adsorption to the interface is sufﬁcient to prevent anye-buffered subphase containing no albumin or chitosan. On compression, the isotherm
expansion, the surface pressure drops rapidly, reaching a minimum surface pressure of
aline-buffered subphase containing 2 mg/mL albumin. The characteristic shoulder and
regardless of the compression. Red curve: The isotherm of a subphase containing 2 mg/
ing that the interfacialﬁlm is dominated byalbumin and that Survanta is not adsorbing to
0.005mg/mL chitosan. By the second compression cycle, the characteristic shoulder and
e of 0.005mg/mL chitosan completely reverses the surfactant adsorption inhibition. The
in the presence of albumin never drops below about 15 mN/m on full expansion, which
ited on a subphase containing 2mg/mL albumin and 0.5mg/mL chitosan. At high trough
cteristic shoulder is evident as in panel a. However, the isotherm only reaches a surface
tes that the increased chitosan concentration decreases surfactant adsorption compared
Fig. 2. Fourth cycle compression isotherms of 800 μg Survanta on a saline buffered subphase containing albumin (2mg/mLwhen present) and the stated chitosan concentrations. (a)
□ Survanta; ○ Survanta–albumin;▹ Survanta–albumin with 0.005 mg/mL chitosan,◃ Survanta–albumin with 0.001 mg/mL chitosan; △ Survanta–albumin with 0.0005 mg/mL
chitosan; V Survanta–albumin with 0.0001 mg/mL chitosan. In this concentration regime, increasing chitosan concentration yields increasing surfactant adsorption. From Table 1,
charge neutralization of the Survanta and albumin is reached between 0.0005–0.005mg/mL chitosan. Note that for .001mg/mL chitosan, more Survanta adsorbs (isotherm shifted to
larger trough areas) than the control Survanta on a clean subphase. (b)□ Survanta;○ Survanta–albumin;△ Survanta–albumin–chitosan 0.5 mg/mL,▽ Survanta–albumin–chitosan
0.1 mg/mL; ◃ Survanta–albumin–chitosan 0.01 mg/mL; ▹ Survanta–albumin–chitosan 0.005 mg/mL. For chitosan concentrations greater than that necessary for charge
neutralization (Table 1), surfactant adsorption decreased. The shaded area denotes the trough area over which the surface pressure was averaged for each chitosan concentration to
obtain the surfactant relative adsorption plotted in Fig. 6.
Fig. 3. Fourth cycle compression isotherms of subphases containing albumin and/or
chitosan without Survanta. □ 2 mg/mL albumin; ○ 2 mg/mL albumin–0.1 mg/mL
chitosan; △ 0.1 mg/mL chitosan. Albumin is surface active while chitosan is not;
chitosan addition does not change the albumin isotherm. Compressing the albumin ﬁlm
increases the surface pressure from about 15 mN/m to a maximum of about 30 mN/m;
expanding the albumin ﬁlm shows a similar hysteresis to the Survanta monolayer as the
surface pressure rapidly drops to b20 mN/m and is roughly constant during the
expansion. This minimum surface pressure is likely set by adsorption of albumin from
solution.
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on a subphase containing 0.005 mg/mL chitosanwith no albumin, the
isotherm is identical to Fig. 1a (data not shown); this shows that the
chitosan is primarily enhancing the adsorption of Survanta to the
interface with minimal alterations of the surfactant properties.
However, further increases in chitosan concentration led to
increasingly poor Survanta performance. Fig. 1d shows that Survanta
(800 μg) deposited onto a subphase containing 2 mg/mL albumin
and 0.5 mg/mL chitosan exhibits an isotherm that is intermediate
between Survanta (Fig. 1a) and Survanta–albumin (Fig. 1b). Here the
isotherm only reaches a maximum surface pressure of Π∼62 mN/m
on full compression (ratio of 4:1 compared to the 2:1 in Fig. 1a, c)
and the characteristic shoulder at Π∼45 mN/m occurs at a
signiﬁcantly lower trough area than Survanta (∼35% vs. ∼60%). The
increased chitosan concentration results in less surfactant adsorption
to the interface than for the lower chitosan concentration (Fig. 1c).
For the depletion attraction induced increase in Survanta adsorption,
surfactant adsorption increased exponentially with polymer concen-
tration up to a saturation concentration; surfactant adsorption did
not decrease [17].
Fig. 2a and b show the effect of varying chitosan concentrations on
Survanta (800 μg) deposited onto a subphase containing 2 mg/mL
albumin; for clarity, only the fourth cycle compression is shown for
each isotherm. Fig. 2a shows that a chitosan concentration of
0.0001 mg/mL (Fig. 2a, pentagons) reaches a maximum surface
pressure of 45 mN/m, similar to the Survanta–albumin isotherm (Fig.
2a, circles). Increasing the chitosan concentration to 0.0005 mg/mL
(Fig. 2a, up-triangles) restores the characteristic shoulder and collapse
plateau at a smaller trough area than Survanta on a clean interface
(Fig. 2a, squares), indicating less total surfactant adsorption [17]. For
chitosan concentrations of 0.001–0.005 mg/mL (Fig. 2a, left-triangles,
right-triangles), the characteristic shoulder and collapse plateau occur
at similar trough areas as Survanta, indicating an equivalent amount of
total surfactant adsorption. In fact, more Survanta adsorbs for the
optimal chitosan concentration of .001 mg/mL than on a clean
interface — the isotherm is shifted to larger trough areas at all surface
pressures. Note that the surface pressures of the characteristic
shoulder and the collapse pressure of the Survanta does not change
with chitosan concentration, once adsorption has been restored.
Fig. 2b shows that increasing the chitosan concentration above this
optimum value yields a gradual decrease in surfactant adsorption.
Increasing chitosan concentrations shift the characteristic shoulder
and collapse plateau to a lower trough area without altering thesurface pressures at which they occur. While surfactant adsorption at
0.5 mg/mL (Fig. 2b, up triangles) is decreased from the optimum
chitosan concentration (0.005 mg/mL, up-triangles), the isotherm is
still representative of an interface with Survanta compared to the
isotherm of albumin alone (Fig. 1b).
Fig. 3 shows the fourth cycle isotherms from subphases containing
albumin and/or chitosan in the absence of Survanta. Chitosan itself is
not surface active (Fig. 3, triangles) at these concentrations; similar
results are found for concentrations ranging from 0.0001–0.5 mg/mL.
The 2 mg/mL albumin isotherm (Fig. 3, squares) is unchanged by
0.1 mg/mL chitosan (Fig. 3, circles); the curves differ by no more than
3 mN/m over the entire cycle. Albumin reaches a maximum surface
pressure of ∼31 mN/m upon compression and a minimum surface
pressure of ∼13 mN/m upon expansion indicating that its adsorption
and surface activity are unchanged by chitosan. Saline buffer
subphases containing 0.0005–0.5 mg/mL chitosan and 2 mg/mL
albumin are optically clear, putting an upper limit on the aggregation
in the bulk. Other reports show that chitosan does not signiﬁcantly
increase the turbidity of an albumin solution at salt concentrations
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aggregation of the albumin in solution [54].
Fig. 4a shows a ﬂuorescence image of the air–water interface after
Survanta adsorption (Π=43 mN/m) on a saline buffer subphase.Fig. 4. Fluorescence images of 800 μg Survanta (doped with 1% mol Texas Red DHPE) spread
appears black in the images. Images are 1023 μm by 789 μm; all images are from the compre
The image shows themottled texture typical of a phase separated lipid/proteinmonolayer. Th
solution. (b) Survanta on a subphase containing 2 mg/mL albumin at π=25 mN/m. The iso
come close to the interface, but cannot spread due to the albumin ﬁlm at the interface. The
images show Survanta on a subphase containing 2 mg/mL albumin and 0.005 mg/mL chitos
isolated bright spots on a homogenous black background shows that Survanta aggregates ca
breaks through the interface; extended (N1000 μm) immiscible Survanta (mottled gray) a
remove albumin from the interface is much greater than the 15–20 mN/m equilibrium sp
between Survanta and albumin domains (f) π=69 mN/m. At the collapse plateau, only Sur
typical of monolayer collapse. As suggested by a recent theoretical model, the collapse folds ar
Several smaller folds have coalesced into the brighter white, larger folds at the arrows, also as
the interface, the ﬁlm morphology is identical to Survanta on a buffered subphase and albu
arrows indicate brighter collapse cracks and folds at which smaller folds have coalesced [52Survanta (doped with 1% mol Texas Red-DHPE) adsorbs to the
interface as a mixture of monolayers (mottled light gray and dark
gray) typical of a phase separated lipid/protein monolayer along with
bright, three-dimensional aggregates that appear to be attached to theat varying subphase compositions. The albumin was not labeled, does not ﬂuoresce and
ssion part of the isotherm. (a) Survanta on a clean, buffered subphase at π=43 mN/m.
e bright spots are Survanta aggregates partially adsorbed to the interface and partially in
lated bright spots on a homogeneous black background shows that Survanta aggregates
albumin effectively prevents Survanta from adsorbing to the interface. The remaining
an during successive compression/expansion cycles. First cycle: (c) π=25 mN/m. The
nnot easily spread due to the albumin ﬁlm at the interface. (d)Π=54 mN/m. Survanta
nd albumin (black) domains coexist on the interface. The surface pressure needed to
reading pressure of albumin. Second cycle: (e) π=43 mN/m. Continued coexistence
vanta is present in the ﬁlm; the images are dominated by the cracks and folds (arrows)
e roughly parallel to each other and are perpendicular to the compression direction [52].
suggested by theory [52]. Third cycle: (g) π=43mN/m. Once albumin is removed from
min does not re-adsorb to the interface under these conditions. (h) π=69 mN/m. The
].
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all surface pressures. In contrast, Fig. 4b shows that ﬂuorescence
images of Survanta spread on a subphase containing 2 mg/mL
albumin (π=25 mN/m) consists of isolated, out-of-focus lighter gray
regions with an overall dark homogeneous background [17,19,20].
Albumin does not ﬂuoresce and appears dark and featureless in the
images. Fig. 4b shows that Survanta cannot reach the interface to form
a monolayer; the interface is dominated by albumin. The surface
pressure does not signiﬁcantly increase (Fig. 1b) on compression as
only albumin is present at the interface.Fig. 5. Fluorescence images of 800 μg Survanta spread on a saline buffered subphase containin
(a) π=25 mN/m during compression. The black homogenous background dominates the
π=18 mN/m during expansion. Survanta breaks through the interface; extended (N1000
interface. Second cycle (c) π=21mN/m during compression. (d) π=18mN/m during expan
cycle. Third cycle (e) π=21 mN/m during compression. (f) π=18 mN/m during expansion.
during compression. (h) π=18mN/m during expansion. Albumin remains on the interface t
Survanta does not adsorb to completely expel the albumin from the interface.Fig. 4c–h show Survanta deposited onto a subphase containing
2 mg/mL albumin and 0.005 mg/mL chitosan during successive
compression/expansion cycles; the mottled Survanta texture gradu-
ally displaces the darker albumin texture from the interface. The
albumin and Survanta do not appear to be miscible at the interface;
rather, a Survanta front displaces the albumin from the interface (see
Movies in Supplemental Materials). Images from the ﬁrst cycle at low
surface pressure (Fig. 4c, π=25) show a homogeneous black,
albumin-covered interface with limited out-of-focus light gray
patches, indicating that the Survanta aggregates cannot reach theg 2mg/mL albumin and 0.5mg/mL chitosan. Images are 1023 μmby 789 μm. First cycle
interface as the albumin prevents the Survanta from spreading as a monolayer. (b)
μm) immiscible Survanta (mottled gray) and albumin (black) domains coexist on the
sion. The albumin and Survanta domains coexist during the compression and expansion
Albumin and Survanta domains coexist on the interface. Fourth cycle (g) π=24 mN/m
hrough the fourth compression and expansion cycle. Apparently a sufﬁcient quantity of
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indicate that in the presence of chitosan, Survanta adsorbs when the
bright aggregates near the interface adsorb to the albumin-covered
interface and are explosively disrupted (see Movie #1 in Supple-
mental Materials). Images from the ﬁrst cycle maximum surface
pressure (Fig. 4d, π=54) show that Survanta has broken through the
albumin ﬁlm; there is coexistence between the Survanta (mottled
bright texture) and albumin (black) with a well-deﬁned interface
between the materials. The coexistence between the extended
(N1000 μm) interfacial domains of Survanta and albumin continues
through the second cycle compression (Fig. 4e, π=43); albumin
remains on the interfacewell above its equilibrium surface pressure of
∼20 mN/m. However, Survanta can maintain a much higher dynamic
surface pressure on compression than the albumin and eventually
forces all of the albumin from the interface (see Movie #2 in
Supplemental Materials) at surface pressures of Π∼60 mN/m
[17,19,20]. To generate this higher dynamic surface pressure, addi-
tional Survanta likely adsorbs from the bright aggregates attached to
the interface to occupy the new interface created as the trough
expands. Images of the second cycle collapse plateau (Fig. 4f, π=69)
show only Survanta and are dominated by the cracks and folds
(arrows) typical at monolayer collapse [17,49]. As suggested by a
recent theoretical model, the collapse folds in Fig. 4f are roughly
parallel to each other and are perpendicular to the compression
direction [52]. Several smaller folds have coalesced into the brighter
white, larger folds at the arrows, also as suggested by this theory [52].
On the third cycle compression, the mottled Survanta texture similar
to Fig. 4a is seen exclusively at all surface pressures (Fig. 4g, π=43)
and the system again forms a collapse plateau with the associated
cracks and folds (Fig. 4h, π=69). The chitosan does not appear to alter
the morphology or phase behavior of the Survanta, the chitosan
primarily acts to enhance Survanta adsorption.
Fig. 5 shows Survanta deposited onto a subphase containing 2 mg/
mL albumin and 0.5 mg/mL chitosan during successive compression/
expansion cycles; here Survanta breaks through interface but never
completely displaces the albumin. Similar to 0.005 mg/mL chitosan,
images from the ﬁrst cycle compression (Fig. 5a, π=25) show a
homogeneous black, albumin-covered interface while images from
the ﬁrst cycle expansion (Fig. 5b, π=18) show that Survanta has
broken through the albumin ﬁlm. During the second and subsequent
cycles, images from the compression and expansion parts of the
isotherm show a continued coexistence of Survanta and albumin
domains; albumin remains on the interface through the fourth cycle.
This behavior is consistent with the isotherm in Fig. 1d, which shows
that the ﬁlm does not achieve the sufﬁciently high surface pressure
needed to expel the albumin from the interface. While 0.5 mg/mL
chitosan enhances surfactant adsorption enough to initially break
through the albumin interface, additional surfactant does not adsorb
on expansion of the ﬁlm to sufﬁciently raise the surface pressure to
entirely eliminate the albumin from the interface. For both chitosan
concentrations (Fig. 4c–h, Fig. 5), the images show the Survanta
morphology similar to the control (Fig. 4a) whether the surfactant
fully displaces or only partially displaces the albumin on the interface.
Chitosan does not change the monolayer microstructure but rather
enhances surfactant adsorption to the interface. A contributing effect
may be that the adsorbed chitosan stabilizes the Survanta in the
aggregate form; chitosan adsorbed to giant unilamellar vesicles
stabilized the spherical bilayer structure against changes in pH or
osmotic pressure [55] that completely disrupted unprotected vesicles.
4. Discussion
Comparison of ﬂuorescence images and isotherms of Survanta
adsorption to clean interfaces [49], or albumin-covered interfaces
with chitosan, electrolyte [19] or PEG in the subphase [17,20] shows
the Survanta morphology and organization at the interface are thesame, conﬁrming that all of these treatments enhance Survanta
transport to the interface while leaving the surfactant essentially
unchanged. For all methods of enhancing adsorption [17,19,20], the
images show that competitive adsorption process is similar:
(1) Albumin initially occupies the entire interface; the smaller size
of albumin compared to Survanta aggregates promotes faster
diffusion to the interface.
(2) Survanta breaks through the albumin ﬁlm during cycling and
coexists with albumin in discrete domains on the interface.
(3) Sufﬁcient Survanta adsorbs such that the surface pressure is
raised to ∼60 mN/m during compression, completely expelling
the albumin from the interface.
(4) Survanta prevents subsequent albumin adsorption to the
interface; the ﬂuorescence images show behavior typical of
Survanta on a clean subphase including cracks and folds at the
collapse plateau.
Albumin expulsion from the interface (step 3) only occurs
completely only over an optimal chitosan concentration range
(0.001–0.005 mg/mL) while higher and lower chitosan concentra-
tions do not fully expel the albumin from the interface. Similarly, at
sub-optimal concentrations of simple electrolytes and PEG, Survanta
can break through the albumin layer in patches, but cannot
completely displace albumin from the interface. Higher concentra-
tions of PEG or electrolyte, however, does allow Survanta to entirely
expel albumin [17,19,20].
The competitive adsorption of lung surfactant and albumin, like
colloid stability, is an example of a kinetically hindered equilibrium.
The surface pressure, Π, is the negative derivative of the energy, Φ,
with respect to the interfacial area, A: Π=− ∂Φ∂A
 
n
[56]. Hence, at
equilibrium, lung surfactant should always displace albumin at an air–
water interface; the equilibrium surface pressure of LS (∼45mN/m) is
much greater than that of albumin (∼20 mN/m). Similarly, most
apparently stable colloidal dispersions should aggregate at equili-
brium [28]. The interactions between colloidal particles are a
combination of the van der Waals/London dispersion attraction [57]
and the double-layer electrostatic repulsion [28] which gives the
functional form of Φ(r) between two colloids of radius, a, at a
separation, r, surface potential, ψs, and ion concentration, ni via the
Debye length, κ−1 = ee0ð ÞkBT= e2
P
i z
2
i ni
  1=2:
Φ rð Þ=32πee0 kBTez
 	2
atanh2
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exp −κ r−2að Þð Þ− aAH
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zi is the valence of the electrolyte in solution and e is the electron
charge. AH is the Hamaker constant that determines the magnitude of
the attractive dispersion forces [57], kB is Boltzmann's constant and T
is the temperature. From Eq. 1, the energy is minimized when r→2a,
or the particles come into contact and aggregate.
While an aggregated state is minimum in energy, for values of r of
order κ−1, the interaction energy (Eq. 1) can go through a local
maximum, Φmax. The rate of aggregation [58] decreases in the
presence of such an energy barrier [59]. The ratio of the diffusion-
limited ﬂux, J0, to the actual ﬂux, J, which is known as the stability
ratio, W, is proportional to the exponential of the maximum in the
interaction energy, Φmax [60]:
W =
J0
J
~exp
Φmax
kBT

 
: ð2Þ
IfΦmax is large compared to the thermal energy, kBT,W is large and
the colloidal dispersion can be stabilized indeﬁnitely against aggrega-
tion [28]. Eq. 2 also shows that any additive to the colloid dispersion
that lowers Φmax will destabilize the dispersion and lead to
ﬂocculation of the colloid [28]. Previous work has shown that Eq. 1
also governs the rate of adsorption of surfactant aggregates to an
Fig. 6. Relative adsorption (RA) of 800 μg Survanta on subphases containing 2 mg/mL
albumin at varying chitosan concentrations.□ Survanta–albumin–chitosan;○ Survanta–
albumin, which as been plotted at a chitosan concentration of 7×10−5 mg/mL for
comparison purposes. RA is the difference between the sample surface pressure (π) and
the surface pressure of the albumin only isotherm (πAlb, red curve in Fig. 1b), divided by
the difference between the clean interface isotherm (no albumin), πSat, and πAlb,
RA= Π−ΠAlbΠSat−ΠAlb jA0 . All surface pressureswere evaluated byaveraging over the same trough
area, A0, denoted by the shaded area in Fig. 2. The relative adsorption increases with
chitosan concentration to an optimumvalue of RA∼1 at .001–0.005mg/mL chitosan and
then decreases with subsequent increases in chitosan concentration. The dashed box
indicates the calculated (Table 1) chitosan concentration range where n+/n−=1
(0.0005–0.005 mg/mL). The optimum RA occurs in this chitosan concentration range
consistent with a chitosan neutralizing the negative surface charge on the albumin and
surfactant, thereby eliminating the electrostatic energy barrier to surfactant adsorption.
Higher chitosan concentrations above n+/n−=1 lead to charge reversal as excess
chitosan adsorbs to the albumin and surfactant, leading to a net positive charge in the
double layer and a restored energy barrier to adsorption (Eqs. 1–3).
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stable colloidal dispersion, the presence of albumin at the interface
creates a steric and electrostatic barrier that slows the rate of
adsorption of surfactant to the interface. Under physiological condi-
tions, Φmax∼6 kBT for Survanta adsorption to an albumin covered
interface [17] which, given the limited time (minutes) available for
surfactant adsorption during expansion of the trough (or the much
shorter times during normal respiration), effectively prevents sufﬁ-
cient surfactant from reaching the interface. Less surfactant at the
interface requires greater compression ratios in vitro to reach a
maximum surface pressure (see Fig. 1d); such compression ratios
might not be achievable in vivo.
It follows that either increasing the attractive interactions or
decreasing the repulsive interactions between surfactant and albumin
should lower Φmax and improve surfactant adsorption. Previous work
[16,17,20,21,27] has shown that non-adsorbing hydrophilic polymers
such as polyethylene glycol, dextran and hyaluronan enhance
surfactant adsorption via increasing the attractive interactions
between the surfactant and the interface via a depletion-attraction
mechanism [41,42]:
Φdep¼−3 a=Rg
 
/pkBT 1− r−2að Þ=2Rg
  2 ð3Þ
Rg is the polymer radius of gyration and ϕp is the polymer volume
fraction [41,42]. Eq. 3 adds an additional attractive term to Eq. 2,
thereby decreasing Φmax. The scaling of surfactant adsorption with
polymer concentration [17] and molecular weight [20] veriﬁed the
predictions of Eqs. 1–3. It is also possible to decrease the electrostatic
repulsion (ﬁrst term in Eq. 1) by increasing the electrolyte concentra-
tion in the suspension, thereby decreasing the Debye length, κ−1, and
hence the magnitude and range of the electrostatic repulsion [19,26].
Increasing the salt concentration from 150 mM to 1 M effectively
restored surfactant adsorption in the presence of albumin [19]. As has
been observed for nearly 100 years in studies of colloidal aggregation
[61,62], surfactant adsorption was very sensitive to the valence, z, of
the positively charged ions in solution.
The effects of chitosan, and by inference, other polycations, on
surfactant adsorption also have direct analogies to colloidal stability.
Polyelectrolytes are used to both stabilize and de-stabilize colloidal
dispersions in wastewater treatment, mineral processing, ceramics
manufacture and papermaking, and the origins of these effects have
been extensively studied [30–35]. Adsorption of cationic polyelec-
trolytes to anionic colloids initially leads to a decrease of the overall
net particle charge with a resulting decrease in the particle surface
potential, ψs, in Eq. 1, thereby reducing Φmax. At a certain polymer
concentration, the net charge in the double-layer is neutralized, ψs
and Φmax in Eq. 1 go to zero, resulting in rapid aggregation [28].
However, with further increases in the polyelectrolyte concentration,
the adsorption continues beyond net neutrality and leads to a charge
reversal of the colloid, restoring ψs andΦmax, leading to a re-stabilized
colloidal dispersion [30–35].
The effects of polyelectrolytes on charge-stabilized colloids parallel
those of the cationic chitosan on the adsorption of the anionic lung
surfactant in the presence of anionic albumin: ﬁrst an increase in
adsorption at low chitosan concentrations, followed by a decrease in
adsorption for higher chitosan concentrations (see. Figs. 2, 6).
Polyelectrolytes, in general, adsorb to surfaces of opposite charge
because the entropy increase caused by the release of the polymer and
surface counter-ions to the solution; the positively charged amide
groups on the chitosan can form ion pairs with oppositely charged
ions on the surfactant and albumin surfaces, until the net charge in the
electrical double layer is neutralized and the surface potential is
reduced to zero (Eq. 1). However, this net neutralization cannot
explain charge reversal; it is necessary to consider the details of the
charge distribution of the surfaces and the polymers.In comparison to a solution of molecular ions like sodium or
calcium, the positive charges on chitosan and other polyelectrolytes
have a maximum and minimum separation ﬁxed by the allowable
polymer conﬁgurations. It is unlikely that the normal separations
between negative charges in Survanta [63] or albumin are compatible
with the separation between amide groups on the chitosan. Hence, a
chitosan molecule with n+ positive charges would not be capable of
forming ion pairs with an equivalent number, n−, of surface charges,
as would be the case for n+ individual sodium ions, for example.
Hence, while n+ positive charges on chitosan adsorbed to the
surfactant or albumin can neutralize the average “smeared” net n−
negative charges in the double layer, resulting in a zero net potential in
Eq.1, the surface itself remains heterogeneous with patches of positive
and negative charges [32,33]. Such a heterogeneous surface can lead
to a short range “dipolar attraction” between the interfacial albumin
and the surfactant bilayer aggregates, leading to a net attractive
interaction between the surfactant and the interface. The can lead to
enhanced adsorption even relative to a clean surface. In Fig. 2a, for
chitosan concentration of .001 mg/mL, the amount of Survanta
adsorbed to the interface in the presence of albumin is even greater
than the control adsorption to a clean interface.
Additional chitosan can continue to adsorb as the polycation sees
both attractive negative and repulsive positive charges on the surface
while the net potential is low. The added chitosan can form ion pairs
with the remaining negative charges on the surfactant or albumin
surfaces. This over-compensation of charge is common; for example,
certain polycations adsorb on net positively charged TiO2 surfaces,
where both positive and negative point charges coexist [35]. The
result is a charge reversal as more positive ions are present in the
vicinity of the surfaces than negative ions; chitosan continues to
adsorb until the surfaces are sufﬁciently positively charged that the
positively charged polymer is repelled from the surface by a now
positive surface potential (Eq. 1) [33–35]. The net positively charged
albumin and surfactant particles again have a repulsive interaction
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adsorption to the interface.
True equilibrium between the polycation and the anionic colloid is
almost never obtained; polyelectrolyte adsorption is yet another case
of kinetically hindered equilibrium. While each electrostatic ion pair
between the polymer and the surface is weak, the large number
possible between the polyelectrolyte (chitosan has ∼500 cationic
amine sites/molecule) and the negative chargesmakes the adsorption
effectively irreversible [30,31,33,35]. Once bound, the polycation
cannot readily adjust its position on the surface to neutralize the
equivalent number of negative charges, especially if the charge
distribution on the polymer does not match that on the surface. If
the adjacent solution is diluted, the pH changed, etc., the polyelec-
trolyte does not necessarily desorb; there is a pronounced adsorption
hysteresis that is typical for kinetically hindered equilibrium. This
irreversibility of adsorption, combined with charge reversal makes
possible the preparation of polyelectrolyte multilayers of anionic and
cationic polymers on a variety of substrates including multilamellar
liposomes [33].
Fig. 6 shows a quantitative demonstration of the effects of this
chitosan-induced charge neutralization followed by charge over-
compensation on the adsorption of lung surfactant to an albumin-
covered interface. Since the area/molecule of Survanta is relatively
constant at a given the surface pressure and temperature [49], the
amount of surfactant adsorbed is proportional to the surface pressure
at a ﬁxed trough area [17]. Hence, the relative adsorption (RA) can be
estimated to be the difference between the sample surface pressure
(π) and the surface pressure of the albumin only isotherm (πAlb, red
curve in Fig. 1b), divided by the difference between the clean interface
isotherm (no albumin), πSat, and πAlb, RA=
Π−ΠAlb
ΠSat−ΠAlb jA0 [17,19,20]. All
surface pressures were evaluated by averaging over the same trough
area (A0) denoted by the shaded area in Fig. 2b. This region showed
the maximum variation in surface pressure. RA increases about 20
times as the chitosan concentration is increased from 0 to 0.005 mg/
mL; subsequent increases in chitosan concentration result in roughly a
ﬁve fold decrease in RA from the maximum. The optimal concentra-
tion range to enhance surfactant adsorption by chitosan (RA∼1) is
0.001–0.005 mg/mL. From Fig. 2a, surfactant adsorption is even
greater at .001 mg/mL chitosan in the presence of albumin than on a
clean interface.
Table 1 shows calculations for the ratio of the positive charges on
chitosan relative to the negative charges on albumin and Survanta,
n+/n−, as a function of chitosan concentration. Two limits of theTable 1
Stenger et. al.
Albumin Chitosan Survanta
Molecular weight 66,430 120,000a 691b
Charge/molecule −2c 509d −0.1e
Chitosan: survanta+albumin: charge ratio
Chitosan concentration, mg/mL 0.0005 0.005 0.05 0.5
n+/n− (Bulk)f 3.46×10−2 0.346 3.46 34.6
n+/n− (Interface)g 2.69 26.9 2.69×102 2.69×103
For chitosan concentrations of 0.0005 and 0.005 mg/mL, the bulk and interfacial charge
ratios bracket an estimate for n+/n−=1 indicating charge neutralization occurs over
this concentration range.
a Average molecular weight of chitosan, 50–190 kDa.
b Calculated molecular weight for DPPC:POPG:PA (70:20:10 wt.), a lipid mixture
similar in composition to Survanta.
c Albumin charge/molecule at pH 5.5 in 150 mM NaCl [75].
d Calculated based on chitosanwith averagemolecular weight of 120,000with 80% of
the monomers containing an amine group with pKa of 6.5 at a pH of 5.5.
e Based on published Survanta composition showing ∼10% anionic lipids [46].
f The charge ratio, n+/n−, of the cationic molecules (chitosan): anionic molecules
(albumin and Survanta). For n+/n− bulk, the bulk concentrations of chitosan,
albumin (2 mg/mL) and Survanta (800 μg/150 mL) are used.
g For n+/n− interface, the interfacial concentration of albumin (5 mg/m2 [64]) and
Survanta (800 μg/130 m2) are compared with the bulk chitosan concentration.charge ratio are considered: (1) comparing the total bulk concen-
trations of Survanta and albumin to chitosan (2) comparing the
interfacial concentrations of Survanta and albumin to the bulk
chitosan concentration. The 800 μg Survanta is spread near the
interface; this amount of Survanta is scaled by the subphase volume
(150 mL) and expanded trough area (130 cm2) and to yield the bulk
and interfacial concentrations. 2 mg/mL is used for the albumin
bulk concentration while 5 mg/m2 is used for the interfacial
concentration [64]. For chitosan concentrations of 0.0005 and
0.005 mg/mL, the bulk and interfacial charge ratios bracket unity
(n+/n−=1). This concentration range is shown as the dashed box
in Fig. 6, which should provide the greatest decrease in both ψs and
Φmax; the concentration range within the dashed box corresponds to
the highest RA. This result is consistent with charge neutralization
leading to enhance surfactant adsorption. The higher adsorption at
.001 mg/mL chitosan is consistent with the formation of a
heterogeneous surface with patches of positive and negative charges
on the surfactant and albumin, which provide a dipolar attraction at
close range. At higher chitosan concentrations, both the bulk and
interfacial charge ratios in Table 1 show that the surfactant and
albumin at the interface are net positively charged, resulting in a
partially restored ψs and Φmax and the albumin inhibition is only
partially reversed. It should be noted that in our system, chitosan
enhances surfactant adsorption (RAN0.2) relative to albumin only
subphases even at chitosan concentrations two orders of magnitude
higher than charge neutralization, yielding a broad window of
enhanced surfactant adsorption. A possible explanation for this
behavior is that, from studies of alternate layer polyelectrolyte
adsorption on surfaces, chitosan and other polyelectrolytes even-
tually saturate the surface and do not continuously increase the
surface charge and surface potential with increasing bulk chitosan
concentration [33,35]. Once the surfaces are saturated, the excess
chitosan and counterions in solution reduces the Debye length, so
that the electrostatic interactions due to the cationic polymers on
the surfaces are shielded by the higher electrolyte concentration and
resulting smaller Debye length (Eq. 1). This likely slows the decrease
in surfactant adsorption with increasing chitosan concentration, just
as we observed for higher electrolyte concentrations in previous
work [19]. This optimal window of enhanced adsorption with the
cation/anion charge ratio is almost identical to that reported for the
stability ratio for chitosan induced ﬂocculation of anionic colloidal
particles [30–32].
The ﬂuorescence images and the invariance of the Survanta
isotherms with chitosan concentration on albumin containing sub-
phases show that Survanta adsorption is enhancedwithout signiﬁcant
alteration of the Survanta interfacial properties. Albumin and Survanta
appear immiscible in the ﬂuorescence images; we observe a well-
deﬁned front of Survanta that displaces the albumin from the interface
(Figs. 4, 5, and Supplemental Material). Zuo et al. [65] observed
changes in bovine lung extract surfactant (BLES) ﬁlmmorphology and
isotherms at low surface pressures which they ascribed to albumin
and BLES ﬁlm miscibility. Kang et al. [43] observed higher minimum
surface tensions and changes in cyclic isotherms at high chitosan
concentrations. The likely explanation for these differences is the
much larger fraction of unsaturated lipids in BLES compared to
Survanta [47], and the resulting larger fraction of liquid expanded (LE)
phase in BLES monolayers compared to Survanta monolayers [49].
Polyelectrolytes interact strongly with LE ﬁlms at low surface
pressures, expanding the monolayer to larger area/molecule at a
given surface pressure [66–69] through both electrostatic interactions
with the head groups and hydrophobic interactions with the tail
groups of the surfactant [68]. The extent of the modiﬁcation of the LE
phases correlates with the unsaturation of the fatty acid chains;
saturated lipids that form LE phases only at lower surface pressures
are less affected than are unsaturated lipids that have larger area/
molecule and do not form LC phases until much higher surface
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the LE phase, many polyelectrolytes, including chitosan, raise the
collapse pressure of unsaturated fatty acid molecules from about 30 to
45 mN/m even though the limiting area/molecule at collapse
increases from about 20 to 40 Å2/molecule [67,69]. The chitosan is
likely matching the minimum separation between charges along its
backbone with the charge separation in the fatty acid ﬁlms and the
cross-linking of the headgroups via the chitosan stabilizes the
monolayer against collapse, in a similar way as divalent ions increase
the collapse pressure and stability of fatty acid ﬁlms [67,70–74].
Hence, the chitosan (and other polyelectrolytes [67]) appear to help
stabilize the LE phase in themonolayer. However, it is generally agreed
that the unsaturated LE phase lipids must be “squeezed-out” in favor
of the LC phase, saturated lipids that can reach the necessary lower
surface tensions on compression [2]. If the unsaturated lipids in BLES
ﬁlms are not removed at low surface pressures, a higher fraction of LE
phase may be retained in the monolayer ﬁlm of BLES, which would
then result in a less stable interfacial ﬁlm and the ﬁlmsmay collapse at
the LE collapse pressure, which while increased by interactions with
chitosan, is still not as high as the LC phase. As Survanta has very little
LE phase at any surface pressure, chitosanwould be expected to have a
much smaller effect on Survanta, as we observe. The same explanation
is likely true for themiscibility of albumin in the surfactant ﬁlm. Zuo et
al. [65] only observe albumin to be soluble in the LE phase; the small
fraction of LE phase in Survanta at high surface pressures would cause
complete exclusion of the albumin from the Survanta ﬁlm and an
immiscible displacement as is observed.
5. Conclusions
Chitosan, when added to the subphase, enhances the competitive
adsorption of the clinical lung surfactant, Survanta, to an albumin-
covered interface over a narrow concentration range. In direct analogy
to chitosan's effects on anionic colloid stability, at the optimal
concentration, the chitosan irreversibly adsorbs to the negatively
charged albumin and Survanta, leading to a net neutralization of
charge in the double layer and an elimination of the electrostatic
barrier to Survanta adsorption. However, as the charge distribution on
albumin, Survanta and chitosan are not perfectly matched, the
albumin and Survanta surfaces, even at net neutrality, likely have
patches of negative charge remaining on the surfaces that can bind
additional chitosan. Hence, on addition of chitosan in excess of that
needed to neutralize the surfaces, the net charge in the double layer is
reversed, leading to a new positive surface potential and a new, likely
different electrostatic barrier to Survanta adsorption, resulting in the
decreased adsorption with increasing concentration that we see.
Every additive known to de-stabilize a charged colloidal suspen-
sion also enhances the competitive adsorption of Survanta: hydro-
philic polymers that induce a depletion attraction [21], increased
concentrations of molecular electrolytes that reduce the Debye length
and screen the double-layer repulsion [19], and polycations that ﬁrst
neutralize the double-layer repulsion, then over compensate and re-
stabilize the colloidal dispersion [33]. The simple analogy between
colloid stability and competitive adsorption appears to be both
qualitatively predictive and quantitatively accurate.
In addition to their generic effects on surfactant adsorption,
albumin and chitosan can have speciﬁc effects that depend on
surfactant composition and phase behavior. For Survanta, both
albumin and chitosan have little effect on either isotherms or ﬁlm
morphology, once Survanta has displaced the albumin from the
interface. The characteristic shoulder in the isotherm (that likely
corresponds with unsaturated lipid squeeze-out) and monolayer
collapse occur at the same surface pressure regardless of chitosan
concentration or the presence of albumin in the subphase. Fluores-
cence images show the same Survanta morphology with chitosan and
albumin in the subphase as for control Survanta on pure buffer.Survanta is immiscible with albumin and displaces the albumin from
the interface at a well-deﬁned boundary with little or no mixing.
Other replacement surfactants, notably bovine lung extract surfactant,
which has a higher fraction of unsaturated lipids and a greater range of
liquid expanded phase, may be more miscible with albumin [65] and
the LE phase behavior is altered by chitosan [43]. Survanta's ability to
retain its high surface pressure at collapse and normal phase behavior
in the presence of albumin and chitosan is likely due to the relatively
small fraction of unsaturated lipids compared to BLES and may make
Survanta performance more predictable in designing new treatments
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